 - Group 2: Severe renal impairment subjects eGFR 30 mLmin1.73m2 Based on safety and pharmacokinetic PK results from subjects with severe renal impairment Group 2, Group 3 Moderate Renal Impairment and Group 4 Mild Renal Impairment will be enrolled if substantial change in the exposure of lasmiditan is observed in subjects with severe renal impairment. 